Antibody-drug conjugates - An emerging class of cancer treatment

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 362-367

  Diamantis, Nikolaos ^a   Banerji, Udai ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

antibody drug conjugate; brentuximab vedotin; cytotoxic payload; linker; MMAE; resistance; T DM1; target antigen

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; DRUG ANTIBODY; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; CHEMISTRY; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84953431794     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.435     Document Type: Review

References (45)

1. Agarwal P, Bertozzi CR. (2015). Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 26(2): 176-192.
2. Barok M, Joensuu H, Isola J. (2014). Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16(2): 209.
3. Baselga J, Verma S, Ro J, Huober J, Guardino E, Fang L, Olsen S, Phillips GL, de Haas S, Pegram M. (2013). Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. AACR Annual Meeting. Abstract LB-63. Presented April 7, 2013.
4. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. (2011). SAR3419: an anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 17(20): 6448-6458.
5. Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK. (2008). Determination of pharmacokinetic values of calicheamicin-Antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol. 61(6): 1027-1035.
6. Bouchard H, Viskov C, Garcia-Echeverria C. (2014). Antibody-drug conjugates-A new wave of cancer drugs. Bioorg Med Chem Lett. 24(23): 5357-5363.
7. Casi G, Neri D. (2012). Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release. 161(2): 422-428.
8. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H, Acute Leukemia French A. (2012). Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 37.9(9825).: 1508-1516.
9. Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, ZandaM, van Dongen GA. (2014). Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res. 74(20): 5700-5710.
10. Flygare JA, Pillow TH, Aristoff P. (2013). Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 81(1): 113-121.
11. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS. (2009). Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood. 113(18): 4352-4361.
12. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366(10): 883-892.
13. Gupta PB, Chaffer CL, Weinberg RA. (2009). Cancer stem cells: mirage or reality?. Nat Med. 15(9): 1010-1012.
14. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I. (2002). Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 13(1): 47-58.
15. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. (2004). Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 10(20): 7063-7070.
16. Hughes B. (2010). Antibody-drug conjugates for cancer: poised to deliver?. Nat Rev Drug Discov. 9(9): 665-667.
17. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. (2011). Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 128(2): 347-356.
18. Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Eugene T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Cherel M. (2014). Radioimmunoconjugates for the treatment of cancer. Semin Oncol. 41(5): 613-622.
19. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. (2011). Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 17(20): 6437-6447.
20. Mack F, Ritchie M, Sapra P. (2014). The next generation of antibody drug conjugates. Semin Oncol. 41(5): 637-652.
21. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, Anderl J, Faulstich H. (2012). Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 104(8): 622-634.
22. Mullard A. (2013). Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 12(5): 329-332.
23. Owonikoko TK, Hussain A, Stadler WM, Smith DC, Sznol M, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli J, Cohen LJ. (2014). A Phase I multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). J Clin Oncol. 32: 5s (suppl; abstr 2558
24. Palakurthi S. (2015). Challenges in SN38 drug delivery: current success and future directions. Expert Opin Drug Deliv. 27: 1-11.
25. Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D. (2011). A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer. 104(7): 1106-1115.
26. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. (2014). Site-specific antibody drug conjugates for cancer therapy. MAbs. 6(1): 34-45.
27. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. (2014). Antibody-drug conjugates: current status and future directions. Drug Discov Today. 19(7): 869-881.
28. Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G, Neri D. (2014). Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 74(9): 2569-2578.
29. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR. (2013). A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 121(24): 4854-4860.
30. Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris 3rd HA, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX. (2014). Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 20(2): 456-468.
31. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 30(18): 2190-2196.
32. Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP. (2013). Long-Term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumorinitiating cells. Mol Cancer Ther. 12(1): 38-47.
33. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. (2011). Investigational antibody drug conjugates for solid tumors. Expert Opin Invest Drugs. 20(8): 1131-1149.
34. Sapra P, Shor B. (2013). Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 138(3): 452-469.
35. Senter PD, Sievers EL. (2012). The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 30(7): 631-637.
36. Shah MA. (2015). Update on metastatic gastric and esophageal cancers. J Clin Oncol. 33(16): 1760-1769.
37. Shefet-Carasso L, Benhar I. (2015). Antibody-Targeted drugs and drug resistance-Challenges and solutions. Drug Resist Updat. 18: 36-46.
38. Sievers EL, Senter PD. (2013). Antibody-drug conjugates in cancer therapy. Ann Rev Med. 64: 15-29.
39. Teicher BA, Chari RV. (2011). Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 17(20): 6389-6397.
40. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W. (2009). A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia. 23(8): 1389-1397.
41. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. (2006). The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 132(4): 398-409.
42. Van Herpen CM, Banerji U, Mommers EC, Koper NP, Goedings P, Lopez J, Awada A, Fiebrich HB, Aftimos PG. (2015). Phase I Dose-Escalation Trial with the DNA-Alkylating Anti-HER2 Antibody-Drug Conjugate SYD985. European Cancer Congress: Vienna, Austria
43. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, Group ES. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 367(19): 1783-1791.
44. Visvader JE, Lindeman GJ. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8(10): 755-768.
45. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin?s lymphoma. J Clin Oncol. 30(18): 2183-2189.